QUICKLINKS AND VIEW OPITONS
Taranabant causes average weight loss of 14.5 lbs in one year vs 5.7 lbs with placebo
Tuesday, April 01, 2008 7:28 am Email this article
A dose of 2 mg of taranabant per day caused an average weight loss of 14.5 lbs in one year when combined with diet compared to 5.7 pounds for those given a placebo according to results presented yesterday at the 57th annual scientific session of the American College of Cardiology. Taranabant is a cannabinoid-1 receptor blocker similar to Acomplia ( rimonabant ). Maximum Weight Loss
Maximum weight loss achieved after 9 months
Maximum weight loss was achieved after 9 months, and was maintained during the remainder of the study.
5% Weight Loss
5% weight loss in 57% on taranabant vs 27% on placebo
Fifty-seven percent ( 57% ) of those on 2 mg of taranabant had lost at least 5% of their body weight after one year compared to 27% of those given a placebo.
10% Weight Loss
10% weight loss in 28% on taranabant vs 8% on placebo
Twenty-eight percent ( 28% ) of those on 2 mg of taranabant had lost at least 10% of their body weight after one year compared to 8% of those given a placebo.
Higher Doses Not Substantially More Effective
4 mg and 6 mg have not caused substantially more weight loss
Apparently, higher doses of 4 mg and 6 mg caused too many side effects compared to the increased weight loss, that the company decided to only continue testing 2 mg.
“During the study, patients taking the taranabant 6 mg dose were re-randomized to receive placebo or taranabant 2 mg (ratio 1:2) following a recommendation by an independent external Data Safety Monitoring Committee (DSMC),” the press release noted.
“Based on the benefit-risk considerations and the lack of a substantial improvement in the efficacy of taranabant at the 4 mg and 6 mg doses seen in our clinical program compared to the 2 mg dose, we have decided to continue to evaluate taranabant in doses up to and including 2 mg in our Phase III studies,” said John Amatruda, M.D., vice president of clinical research, Metabolic Disorders, Merck Research Laboratories.
Subjects : 417 on placebo, 414 on 2mg, 415 on 4 mg, 1256 on 6 mg
The study involved 417 people who received placebo, 414 people who received 2 mg of taranabant, 415 people who received 4 mg of tarnabant, and 1256 people who received 6 mg of taranabant.
Those receiving 4 mg and 6 mg were re-randomized during the study to receive placebo or 2 mg of taranabant.
Merck & Co., Inc. Phase iii data showed taranabant, merck’s investigational medicine to treat obesity, led to statistically significant weight loss. Press release issued by Merck & Co, Inc. 2008 Mar 31.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.